D. Boral Capital Reaffirms “Buy” Rating for Kairos Pharma (NYSEAMERICAN:KAPA)

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Kairos Pharma Price Performance

KAPA opened at $1.35 on Wednesday. Kairos Pharma has a twelve month low of $0.85 and a twelve month high of $4.00.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.